Pfizer Stock Gains Amid Dividend Appeal and Valuation Debate
Pfizer Inc. (NYSE: PFE) is drawing renewed investor interest as its high dividend yield and discounted valuation spark Wall Street debates. The stock closed at $26.03, nearing its 52-week high, with a market cap of $148 billion and a beta signaling low volatility. A 6.6% dividend yield makes it a standout for income-focused portfolios.
While pandemic-era vaccine revenues decline, Pfizer's non-COVID portfolio shows resilience. The acquisition of Metsera has reignited ambitions in the obesity-drug market, positioning the company for late-decade growth. Analysts are divided on whether the stock represents a deep-value opportunity or carries hidden long-term risks.